A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

AIMS: Stroke is often a devastating event among patients with heart failure with reduced ejection (HFrEF). In COMMANDER HF, rivaroxaban 2.5 mg b.i.d. did not reduce the composite of first occurrence of death, stroke, or myocardial infarction compared with placebo in patients with HFrEF, coronary art...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehra, Mandeep R, Vaduganathan, Muthiah, Fu, Min, Ferreira, João Pedro, Anker, Stefan D, Cleland, John G F, Lam, Carolyn S P, van Veldhuisen, Dirk J, Byra, William M, Spiro, Theodore E, Deng, Hsiaowei, Zannad, Faiez, Greenberg, Barry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Fast Track Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868495/
https://www.ncbi.nlm.nih.gov/pubmed/31461239
http://dx.doi.org/10.1093/eurheartj/ehz427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868495/
https://www.ncbi.nlm.nih.gov/pubmed/31461239
http://dx.doi.org/10.1093/eurheartj/ehz427

Ejemplares similares